- Home
- AUUD vs CDT Comparison
AUUD vs CDT Comparison
Compare AUUD & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- CDT
- Stock Information
- Founded
- AUUD 2012
- CDT 2019
- Country
- AUUD United States
- CDT United States
- Employees
- AUUD N/A
- CDT N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- CDT Health Care
- Exchange
- AUUD Nasdaq
- CDT Nasdaq
- Market Cap
- AUUD 4.1M
- CDT 4.2M
- IPO Year
- AUUD 2021
- CDT N/A
- Fundamental
- Price
- AUUD $1.22
- CDT $2.38
- Analyst Decision
- AUUD
- CDT
- Analyst Count
- AUUD 0
- CDT 0
- Target Price
- AUUD N/A
- CDT N/A
- AVG Volume (30 Days)
- AUUD 2.0M
- CDT 611.0K
- Earning Date
- AUUD 11-07-2025
- CDT 11-14-2025
- Dividend Yield
- AUUD N/A
- CDT N/A
- EPS Growth
- AUUD N/A
- CDT N/A
- EPS
- AUUD N/A
- CDT N/A
- Revenue
- AUUD N/A
- CDT N/A
- Revenue This Year
- AUUD N/A
- CDT N/A
- Revenue Next Year
- AUUD N/A
- CDT N/A
- P/E Ratio
- AUUD N/A
- CDT N/A
- Revenue Growth
- AUUD N/A
- CDT N/A
- 52 Week Low
- AUUD $1.22
- CDT $2.39
- 52 Week High
- AUUD $14.60
- CDT $2,198.40
- Technical
- Relative Strength Index (RSI)
- AUUD 29.98
- CDT 49.84
- Support Level
- AUUD $1.22
- CDT $2.39
- Resistance Level
- AUUD $1.37
- CDT $3.22
- Average True Range (ATR)
- AUUD 0.15
- CDT 0.32
- MACD
- AUUD -0.02
- CDT -0.13
- Stochastic Oscillator
- AUUD 5.79
- CDT 0.85
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.